COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson’s disease (PD): relevance for motor and non-motor features
Angelo Antonini1, Giovanni Abbruzzese2, Paolo Barone3, Ubaldo Bonuccelli4, Leonardo Lopiano5, Marco Onofrj6, Mario Zappia7, Aldo Quattrone81Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy; 2Movement Disorder Unit, Neurology, University of Genoa, Genoa, Italy; 3Dipartimento di...
Guardado en:
Autores principales: | Angelo Antonini, Giovanni Abbruzzese, Paolo Barone, Ubaldo Bonuccelli, Leonardo Lopiano, et al |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/498b805accd94d8884073e3f5a8b38df |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Beneficial effect of pramipexole for motor function and depression in Parkinson’s disease
por: Osamu Kano, et al.
Publicado: (2009) -
Sleep disorders in Parkinson’s disease
por: Israt Jahan, et al.
Publicado: (2009) -
Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson’s disease: implications for patients
por: Antonini A, et al.
Publicado: (2011) -
Impact of non-motor symptoms in Parkinson’s disease: a PMDAlliance survey
por: Hermanowicz N, et al.
Publicado: (2019) -
Levodopa in the treatment of Parkinson’s disease: an old drug still going strong
por: Werner Poewe, et al.
Publicado: (2010)